NASDAQ$AKBA
Akebia Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Akebia reported third quarter financial results and highlighted recent company milestones.
Akebia Therapeutics reported a total revenue of $48.8 million for Q3 2021, a decrease compared to $60.0 million for Q3 2020, primarily due to lower collaboration revenue from Otsuka. Net loss was $59.5 million for the third quarter of 2021 compared to $60.0 million for the third quarter of 2020. Net product revenue for Auryxia was $36.8 million for the third quarter of 2021 compared to $34.4 million for the third quarter of 2020.
- Pre-commercialization activities are underway in anticipation of March 29, 2022 PDUFA date.
- Vadadustat marketing authorization application submitted to the European Medicines Agency.
- Auryxia net product revenue reached $36.8 million.
- Company settled all patent litigation related to Auryxia, allowing generic versions beginning in March 2025.
Headline financials
Revenue & EPS history
Akebia · Revenue · Quarterly
$48.8M
Revenue by segment
Akebia · $48.8M total across 2 segments · Q3 2021
- Auryxia$36.8M+7.0%75.4%
- License & other revenue$12M-53.1%24.6%
Forward guidance
Akebia is focused on pre-commercialization activities for vadadustat and supporting Auryxia revenue growth.
Tailwinds
- Anticipating potential U.S. launch of vadadustat in 2022.
- Preparing for vadadustat's approval by the FDA.
- Renal sales force is ready for launch.
- Working with partners for successful launch.
- Focusing on broad access initiatives.
Headwinds
- Approval of vadadustat is subject to regulatory review.
- Potential for generic entrants for Auryxia.
- Reliance on third parties for development and manufacturing.
- Competition in the market.
- Changes in economic and financial conditions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-2.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.1%
Avg return
30 days after
41%
19 / 46 earnings
Positive
+34.4%
Q1 2020
Best reaction
-22.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -20.3% | -20.3% | -36.7% | |
| Q4 2025 | +9.9% | +0.8% | +10.7% | |
| Q3 2025 | -18.4% | -18.1% | -20.1% | |
| Q1 2025 | +6.6% | +0.8% | +61.4% | |
| Q4 2024 | -12.4% | +32.1% | -14.5% | |
| Q3 2024 | -3.0% | -2.5% | +2.5% | |
| Q2 2024 | +0.0% | +20.7% | +21.6% | |
| Q1 2024 | -13.6% | -12.1% | -24.3% | |
| Q4 2023 | +20.6% | +29.8% | +3.5% | |
| Q3 2023 | -16.5% | -15.3% | +3.7% | |
| Q2 2023 | +10.4% | +12.0% | -5.6% | |
| Q1 2023 | -3.7% | +3.7% | +17.4% | |
| Q4 2022 | -22.4% | -33.7% | -47.6% | |
| Q3 2022 | +1.9% | +2.6% | +9.0% | |
| Q2 2022 | +1.0% | +3.6% | -2.8% | |
| Q1 2022 | +11.2% | +16.6% | +15.6% | |
| Q4 2021 | +13.4% | +12.0% | -66.8% | |
| Q3 2021 | -12.3% | -14.4% | -24.6% | |
| Q2 2021 | +10.5% | +6.5% | +22.2% | |
| Q1 2021 | +2.6% | +10.6% | +17.9% | |
| Q4 2020 | -19.2% | -17.5% | -26.2% | |
| Q3 2020 | -7.4% | +0.8% | +19.8% | |
| Q2 2020 | -6.4% | -4.1% | -75.9% | |
| Q1 2020 | +34.4% | +38.3% | +40.6% | |
| Q4 2019 | -13.8% | -27.0% | -13.0% | |
| Q3 2019 | -9.6% | -8.2% | +73.5% | |
| Q2 2019 | +20.5% | +22.4% | +11.2% | |
| Q1 2019 | +1.5% | -0.7% | -26.8% | |
| Q4 2018 | -0.9% | +2.7% | -15.3% | |
| Q3 2018 | +10.3% | -4.2% | +5.0% | |
| Q2 2018 | -18.1% | -22.1% | -20.8% | |
| Q1 2018 | +0.7% | +11.0% | +10.5% | |
| Q4 2017 | -10.6% | -12.6% | -28.9% | |
| Q3 2017 | -12.6% | -12.8% | -8.5% | |
| Q2 2017 | +6.8% | +9.4% | +26.0% | |
| Q1 2017 | -2.3% | +2.2% | +8.2% | |
| Q4 2016 | -12.6% | -9.3% | -11.1% | |
| Q3 2016 | +10.6% | +14.1% | +9.9% | |
| Q2 2016 | -9.6% | -7.4% | -3.8% | |
| Q1 2016 | -8.8% | — | — | |
| Q4 2015 | -2.4% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +3.3% | — | — | |
| Q3 2014 | -3.2% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro